CAJ | 학술논문

目的：检测晚期非小细胞肺癌（NSCLC）患者化疗前后T细胞亚群（CD3+、CD3+CD4+、CD3+CD8+、CD4/CD8）的变化，观察细胞免疫状态并探讨免疫治疗的意义。方法对25例晚期NSCLC患者化疗前后检测外周血T细胞亚群，并进行分析。结果25例化疗前与1，2个周期化疗后对照比较差异均无统计学意义。化疗有效组12例，化疗后免疫功能有升高趋势，但无统计学差异；化疗无效组13例，与化疗前T细胞亚群比较无统计学差异。结论晚期NSCLC患者免疫功能可能降低，但化疗无论有无疗效，细胞免疫功能无明显抑制，提示化疗过程中免疫治疗并非必要。
목적：검측만기비소세포폐암（NSCLC）환자화료전후T세포아군（CD3+、CD3+CD4+、CD3+CD8+、CD4/CD8）적변화，관찰세포면역상태병탐토면역치료적의의。방법대25례만기NSCLC환자화료전후검측외주혈T세포아군，병진행분석。결과25례화료전여1，2개주기화료후대조비교차이균무통계학의의。화료유효조12례，화료후면역공능유승고추세，단무통계학차이；화료무효조13례，여화료전T세포아군비교무통계학차이。결론만기NSCLC환자면역공능가능강저，단화료무론유무료효，세포면역공능무명현억제，제시화료과정중면역치료병비필요。
Objective To detect the changes of T cell subsets(CD3+、CD3+CD4+、CD3+CD8+、CD4/CD8)before and after chemotherapy in patients with advanced NSCLC, and observe the changes of the immune status of patients before and after chemotherapy, and explore the significance with a timely and reasonable immunotherapy in patients. Methods Choose 25 patients with advanced NSCLC and observed the changes of the T cell subsets in patients before and after chemotherapy. Results Comparing the ratio of CD3+、CD3+CD4+、CD3+CD8+、CD4+/CD8+between 25 patients after chemotherapy , the difference has not statistically significant, P>0.05; Comparing the T cell subsets before chemotherapy respectively with after the first and second chemotherapy , P>0.05; After two period chemotherapy, the valid group has 12 patients,the ratios of CD3+、CD3+CD4+、CD4+/CD8+ are rising, but P>0.05; Invalid Group has 13 patients, the difference has not too. Conclusion the immune function of patients with advanced NSCLC after chemotherapy or without treatment,not significantly inhibit cellular immune function of patients with advanced NSCLC chemotherapy immune therapy is not necessary in the process.